Cohort study
Arterial Thromboembolism in Patients With Atrial Fibrillation/flutter (AF) and CHA2DS2-VASc Score 0-2 With and Without Cancer
- Retrospective cohort study
- population-based
- matched
Authors' conclusion
In AF patients with CHA2DS2-VASc scores of 0 to 2, newly diagnosed cancer is associated with an increased incidence of stroke, transient ischemic attack, or systemic ATE compared with matched controls without cancer.
Study context
- Population
- Patients with AF and CHA2DS2-VASc score 0 to 2 not receiving anticoagulation at cancer diagnosis (or matched index date); no prior embolic arterial thromboembolism (ATE) or cancermatched cohorts
- Participants
- 1,411 vs 4,233
- Exposure
- AF with cancer vs AF without cancer
- AF and cancern = 1,411
- AF and no cancern = 4,233reference
- Outcome
- Acute ATE (ischemic stroke, TIA or systemic ATE), from hospitalization ICD codes
- Follow-up
- 12 months
Main finding
12-month cumulative incidence of ATE
Hazard ratio
2.70
95% CI 1.65–4.41
By group
AF and cancer vs AF and no cancer
HR 2.70 (95% CI 1.65–4.41)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| ATE in men with CHA2DS2-VASc = 1 and women with CHA2DS2-VASc = 2 (subgroup; highest risk) | 6.07 (2.45–15.01) | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Arterial Thromboembolism in Patients With AF and CHA2DS2-VASc Score 0-2 With and Without Cancer. JACC CardioOncol. Published 17 January 2023. doi:10.1016/j.jaccao.2022.08.014
Summarised from the published abstract; every number is checked against it